MetaCap

Arcturus Therapeutics Holdings Inc. (ARCT)

NASDAQ: ARCTHealth CareBiotechnology: Pharmaceutical PreparationsUSD

7.45-0.15 (-1.97%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ARCT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$214.73M
EPS (TTM)
-$3.10
52-week range
5.50 – 17.96
Day range
7.31 – 7.73
Volume / Avg
601.93K / 851.45K
Beta
—

52-week range

$5.50$17.96

ARCT stock today

Arcturus Therapeutics (ARCT) closed at $7.45 on Nov 20, down 1.97% (-$0.15), versus the S&P 500's 3.70% decline. At this level, ARCT sits near the bottom of its 52-week range of $5.50 to $17.96: 58.5% below the high, set on Sep 17, 2026 and 35.5% above the low. ARCT is up 21.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 19.0%.

Arcturus Therapeutics has posted a net loss over the last twelve months (EPS of -$3.10), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Arcturus Therapeutics

Company profile

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Joseph E. Payne M.Sc.
Headquarters
San Diego, CA
Employees
106
IPO year
2013

Financial highlights

Full financials

In fiscal 2025, Arcturus Therapeutics generated $82.0 million in revenue, down 46.1% from fiscal 2024, its first annual decline since 2024. Arcturus Therapeutics reported a net loss of $65.8 million, compared with a loss of $80.9 million a year earlier. Operating margin was -93.0%.

Arcturus Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$82.03M$152.31M$166.80M$206.00M$12.36M
Growth-46.14%-8.69%-19.03%+1566.79%+29.56%
Net income$-65.78M$-80.94M$-29.73M$9.35M$-203.67M
EPS (diluted)$-2.40$-3.00$-1.12$0.35$-7.74

Analyst forecast

Forecast

Consensus (13 analysts)

strong_buy

Avg. price target

$23.70+218.12%

  • Strong buy 1
  • Buy 10
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $9.00High $40.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.26 vs $-0.60
Surprise
+56.67%

ARCT news

All ARCT news

Arcturus Therapeutics peers

Health Care sector
ARCT peer companies
CompanyPrice% ChgMarket capCompare
PYXSPyxis Oncology Inc.1.81+7.74%$216.49Mvs ARCT
KROSKeros Therapeutics Inc.11.08-2.72%$217.44Mvs ARCT
RCKTRocket Pharmaceuticals Inc.1.95-7.58%$217.74Mvs ARCT
IMRXImmuneering Corporation Class A3.38-2.03%$218.90Mvs ARCT
CYPHCypherpunk Technologies Inc.1.41-18.02%$210.15Mvs ARCT
VNDAVanda Pharmaceuticals Inc.3.45-6.13%$208.32Mvs ARCT
ENTAEnanta Pharmaceuticals Inc.7.62-4.51%$222.19Mvs ARCT
FTHFaeth Therapeutics Inc.7.88-9.32%$203.65Mvs ARCT

Indexes, lists and sector

Arcturus Therapeutics stock FAQ

What is Arcturus Therapeutics's stock price today?

ARCT last traded at $7.45 as of Nov 20, 4:00 PM EST, down 1.97% on the day. Prices are delayed at least 15 minutes.

Does Arcturus Therapeutics pay a dividend?

No. Arcturus Therapeutics does not currently pay a regular cash dividend.

Who is Arcturus Therapeutics's CEO?

Mr. Joseph E. Payne M.Sc. is the chief executive officer of Arcturus Therapeutics Holdings Inc., which has about 106 employees.

Has ARCT ever split its stock?

Yes. The most recent ARCT stock split was a 1-for-7 split on Nov 16, 2017.

What is the ARCT 52-week high?

The 52-week high for ARCT is $17.96 and the 52-week low is $5.50. The stock is currently 58.5% below its high.

Compare ARCT